HES
MCID: HYP810
MIFTS: 57

Hypereosinophilic Syndrome, Idiopathic (HES)

Categories: Blood diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Hypereosinophilic Syndrome, Idiopathic

MalaCards integrated aliases for Hypereosinophilic Syndrome, Idiopathic:

Name: Hypereosinophilic Syndrome, Idiopathic 57 40
Idiopathic Hypereosinophilic Syndrome 59 29 55 6 73
Hypereosinophilic Syndrome, Idiopathic, Resistant to Imatinib 57 13 6
Hes 57

Characteristics:

Orphanet epidemiological data:

59

OMIM:

57
Inheritance:
somatic mutation
isolated cases

Miscellaneous:
occurs at age 20-50 years
considered a myeloproliferative disorder
usually fatal
more common in men (9:1 male:female ratio)


HPO:

32
hypereosinophilic syndrome, idiopathic:
Inheritance somatic mutation sporadic


Classifications:



External Ids:

OMIM 57 607685
Orphanet 59 ORPHA3260
ICD10 via Orphanet 34 D47.5
UMLS via Orphanet 74 C0206141
MedGen 42 C0206141
UMLS 73 C0206141

Summaries for Hypereosinophilic Syndrome, Idiopathic

MalaCards based summary : Hypereosinophilic Syndrome, Idiopathic, also known as idiopathic hypereosinophilic syndrome, is related to primary hypereosinophilic syndrome and hypereosinophilic syndrome, and has symptoms including pruritus and myalgia. An important gene associated with Hypereosinophilic Syndrome, Idiopathic is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are ERK Signaling and Activation of cAMP-Dependent PKA. The drugs Omalizumab and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver, and related phenotypes are splenomegaly and hepatomegaly

Description from OMIM: 607685

Related Diseases for Hypereosinophilic Syndrome, Idiopathic

Diseases related to Hypereosinophilic Syndrome, Idiopathic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 325)
# Related Disease Score Top Affiliating Genes
1 primary hypereosinophilic syndrome 31.9 FIP1L1 PDGFRA PDGFRB
2 hypereosinophilic syndrome 31.6 FIP1L1 IL3 IL5 KIT PDGFRA PDGFRB
3 endomyocardial fibrosis 31.5 FIP1L1 PDGFRA
4 eosinophilic gastroenteritis 29.9 IL3 IL5
5 mastocytosis 29.8 FIP1L1 KIT PDGFRA PDGFRB
6 systemic mastocytosis 29.5 FIP1L1 KIT PDGFRA PDGFRB
7 acute leukemia 29.4 IL3 KIT WT1
8 myelodysplastic syndrome 28.9 IL3 KIT PDGFRB WT1
9 chronic eosinophilic leukemia 28.9 FIP1L1 KIT PDGFRA PDGFRB WT1
10 polyarteritis nodosa, childhood-onset 11.4
11 tooth agenesis, selective, 5 11.4
12 lymphocytic hypereosinophilic syndrome 11.3
13 episodic angioedema with eosinophilia 11.2
14 ovalocytosis, southeast asian 11.2
15 secondary hypereosinophilic syndrome 11.2
16 hepatic encephalopathy 11.2
17 ruijs-aalfs syndrome 11.1
18 epilepsy 11.1
19 learning disability 11.1
20 cataract 32, multiple types 11.1
21 centralopathic epilepsy 11.1
22 craniosynostosis 1 11.1
23 elastosis perforans serpiginosa 11.1
24 emphysema, congenital lobar 11.1
25 carney complex, type 1 11.1
26 peroxisome biogenesis disorder 1a 11.1
27 fanconi anemia, complementation group c 11.1
28 farber lipogranulomatosis 11.1
29 renal glucosuria 11.1
30 neuraminidase deficiency 11.1
31 testicular regression syndrome 11.1
32 werner syndrome 11.1
33 arts syndrome 11.1
34 hypophosphatemic rickets, x-linked dominant 11.1
35 lowe oculocerebrorenal syndrome 11.1
36 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 11.1
37 spastic paraplegia, ataxia, and mental retardation 11.1
38 malaria, mild 11.1
39 dystonia, dopa-responsive, due to sepiapterin reductase deficiency 11.1
40 macs syndrome 11.1
41 hemorrhage, intracerebral 11.1
42 cole disease 11.1
43 blood group, gerbich system 11.1
44 al-raqad syndrome 11.1
45 obstructive nephropathy 11.1
46 immunodeficiency-centromeric instability-facial anomalies syndrome 11.1
47 lyme disease 11.1
48 spindle cell hemangioma 11.1
49 hashimoto encephalopathy 11.0
50 ehrlichiosis 11.0

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome, Idiopathic:



Diseases related to Hypereosinophilic Syndrome, Idiopathic

Symptoms & Phenotypes for Hypereosinophilic Syndrome, Idiopathic

Symptoms via clinical synopsis from OMIM:

57
Abdomen Spleen:
splenomegaly

Skin Nails Hair Skin:
pruritus

Muscle Soft Tissue:
myalgia

Cardiovascular Heart:
restrictive cardiomyopathy
cardiac infiltration of eosinophils
endomyocardial fibrosis

Neurologic Peripheral Nervous System:
peripheral nervous system involvement

Immunology:
no concurrent parasitic infection
no concurrent allergies

Abdomen Liver:
hepatomegaly

Cardiovascular Vascular:
venous thrombosis

Respiratory Lung:
pulmonary infiltrates

Neurologic Central Nervous System:
paraspinal masses
cauda equina syndrome

Hematology:
sustained eosinophilia (greater than 1,500/cubic mm) for greater than 6 months
total white blood cell count less than 25,000/cubic mm with 30-70% eosinophils
bone marrow biopsy shows increased eosinophils without myeloblasts


Clinical features from OMIM:

607685

Human phenotypes related to Hypereosinophilic Syndrome, Idiopathic:

32 (show all 11)
# Description HPO Frequency HPO Source Accession
1 splenomegaly 32 HP:0001744
2 hepatomegaly 32 HP:0002240
3 pruritus 32 HP:0000989
4 venous thrombosis 32 HP:0004936
5 myalgia 32 HP:0003326
6 abnormality of the nervous system 32 HP:0000707
7 eosinophilia 32 HP:0001880
8 pulmonary infiltrates 32 HP:0002113
9 myeloproliferative disorder 32 HP:0005547
10 restrictive cardiomyopathy 32 HP:0001723
11 endocardial fibrosis 32 HP:0006685

UMLS symptoms related to Hypereosinophilic Syndrome, Idiopathic:


pruritus, myalgia

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.66 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.66 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.66 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.66 KIT TGFA WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.66 KIT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.66 TGFA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.66 KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.66 WT1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.66 WT1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.66 KIT WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.66 WT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.66 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.66 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.66 WT1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.66 KIT TGFA WT1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.66 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.66 KIT

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome, Idiopathic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.77 IL5 KIT PDGFRA PDGFRB TGFA
2 immune system MP:0005387 9.73 IL5 KIT PDGFRA PDGFRB TGFA WT1
3 embryo MP:0005380 9.72 IL5 KIT PDGFRA PDGFRB WT1
4 muscle MP:0005369 9.55 KIT PDGFRA PDGFRB TGFA WT1
5 neoplasm MP:0002006 9.26 IL5 KIT PDGFRA WT1
6 reproductive system MP:0005389 9.1 IL5 KIT PDGFRA PDGFRB TGFA WT1

Drugs & Therapeutics for Hypereosinophilic Syndrome, Idiopathic

Drugs for Hypereosinophilic Syndrome, Idiopathic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
6
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
7 glucocorticoids Phase 4,Phase 3,Phase 2
8 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
9 Neurotransmitter Agents Phase 4,Phase 2
10 Adrenergic beta-Agonists Phase 4,Phase 2
11 Adrenergic Agonists Phase 4,Phase 2
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Adrenergic Agents Phase 4,Phase 2
14 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2
15 Anti-Allergic Agents Phase 4,Phase 2
16 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
17 Respiratory System Agents Phase 4,Phase 3,Phase 2
18 Tocolytic Agents Phase 4,Phase 2
19 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
20 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Bronchodilator Agents Phase 4,Phase 2
22 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2
24 Albuterol Phase 4,Phase 2
25 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
28 Hormone Antagonists Phase 4,Phase 3,Phase 2
29 Hormones Phase 4,Phase 3,Phase 2
30 Methylprednisolone acetate Phase 4,Phase 3
31 Prednisolone acetate Phase 4,Phase 3
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
33 Antiemetics Phase 4,Phase 3,Phase 2
34 Neuroprotective Agents Phase 4,Phase 3
35 Protective Agents Phase 4,Phase 3,Phase 2
36
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
37
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
38
Thioguanine Approved Phase 3 154-42-7 2723601
39
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
40
Daunorubicin Approved Phase 3 20830-81-3 30323
41
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
42
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
43
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
44 Reslizumab Approved, Investigational Phase 3,Phase 2
45 Pharmaceutical Solutions Phase 3,Phase 2
46 Bone Density Conservation Agents Phase 3
47 Calcium, Dietary Phase 3
48 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
49 N-Methylaspartate Phase 3
50 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 Corticosteroids
2 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
3 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
4 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
5 Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Terminated NCT00097370 Phase 3 mepolizumab
6 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Recruiting NCT03306043 Phase 3 Mepolizumab
7 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
8 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
9 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
10 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
11 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
12 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
13 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
14 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Completed NCT03052725 Phase 3 reslizumab
15 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
16 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
17 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
18 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
19 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
20 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
21 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
22 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
23 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
24 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
25 A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome Terminated NCT00171860 Phase 2 imatinib mesylate
26 Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02130882 Phase 2 benralizumab
27 Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02101138 Phase 2 Dexpramipexole
28 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
29 Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Recruiting NCT00044304 Phase 2 Imatinib Mesylate
30 Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Completed NCT00086658 Phase 2 mepolizumab
31 Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Withdrawn NCT00230334 Phase 2 Gleevec
32 Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Not yet recruiting NCT03801434 Phase 2 Ruxolitinib
33 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
34 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
35 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) Completed NCT00483067 Phase 2 2-CdA;Ara-C;G-CSF (Granulocyte colony-stimulating factor)
36 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
37 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
38 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
39 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Completed NCT00555581 Phase 2 Imatinib Mesylate
40 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
41 Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy Active, not recruiting NCT02071901 Phase 2 eltrombopag olamine
42 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
43 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067 Phase 2 deferasirox
44 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
45 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
46 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
47 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide
48 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
49 Cilengitide in Treating Patients With Acute Myeloid Leukemia Terminated NCT00089388 Phase 2 cilengitide
50 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine

Search NIH Clinical Center for Hypereosinophilic Syndrome, Idiopathic

Genetic Tests for Hypereosinophilic Syndrome, Idiopathic

Genetic tests related to Hypereosinophilic Syndrome, Idiopathic:

# Genetic test Affiliating Genes
1 Idiopathic Hypereosinophilic Syndrome 29 PDGFRA

Anatomical Context for Hypereosinophilic Syndrome, Idiopathic

MalaCards organs/tissues related to Hypereosinophilic Syndrome, Idiopathic:

41
Bone, Bone Marrow, Liver, Heart, T Cells, Lung, Prostate

Publications for Hypereosinophilic Syndrome, Idiopathic

Articles related to Hypereosinophilic Syndrome, Idiopathic:

(show top 50) (show all 262)
# Title Authors Year
1
A Case of Pulmonary Hypertension Associated with Idiopathic Hypereosinophilic Syndrome. ( 29794385 )
2018
2
Fatal Outcome of Imatinib in a Patient with Idiopathic Hypereosinophilic Syndrome. ( 29780651 )
2018
3
Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab. ( 29998055 )
2018
4
EXPRESS: Idiopathic hypereosinophilic syndrome with pulmonary hypertension. ( 30036150 )
2018
5
Acute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome. ( 30237972 )
2018
6
Eyelid Swelling and Subconjunctival Infiltration as Ophthalmic Manifestations in a Child with Idiopathic Hypereosinophilic Syndrome. ( 30549476 )
2018
7
Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritis. ( 28378039 )
2017
8
Idiopathic hypereosinophilic syndrome with 20 years of diagnostic delay. ( 28577656 )
2017
9
When a death apparently associated to sexual assault is instead a natural death due to idiopathic hypereosinophilic syndrome: The importance of gamma-hydroxybutyric acid analysis in vitreous humor. ( 28527983 )
2017
10
The right atrium in idiopathic hypereosinophilic syndrome : Insights from the 3D speckle tracking echocardiographic MAGYAR-Path Study. ( 29234843 )
2017
11
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. ( 28495918 )
2017
12
Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia. ( 27294613 )
2016
13
Idiopathic Hypereosinophilic Syndrome Associated with Endomyocardial Fibrosis, Intracardiac Thrombi, Pulmonary and Skin Infiltration: A Case Report. ( 27617583 )
2016
14
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. ( 27174585 )
2016
15
Eosinophilic pleural effusion as a manifestation of idiopathic hypereosinophilic syndrome. ( 27185511 )
2016
16
Idiopathic hypereosinophilic syndrome presenting as angina pectoris: A case report. ( 27521535 )
2016
17
Idiopathic hypereosinophilic syndrome. ( 27728301 )
2016
18
Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. ( 27803915 )
2016
19
Idiopathic hypereosinophilic syndrome resulting in distal aortic thromboembolism in a dog. ( 27723953 )
2016
20
A Rare Case of Aortic Valve Thrombosis in Patient with Idiopathic Hypereosinophilic Syndrome. ( 26435854 )
2015
21
A Case of Idiopathic Hypereosinophilic Syndrome Causing Mitral Valve Papillary Muscle Rupture. ( 26640733 )
2015
22
Tricuspid valve surgery in patients with idiopathic hypereosinophilic syndrome. ( 25472741 )
2015
23
Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. ( 26497854 )
2015
24
Endobronchial Involvement in Idiopathic Hypereosinophilic Syndrome. ( 26492606 )
2015
25
Pyoderma gangrenosum in association with microscopic colitis, idiopathic hypereosinophilic syndrome, selective IgE deficiency and diabetes mellitus. ( 25704069 )
2015
26
Idiopathic Hypereosinophilic Syndrome With Cutaneous Manifestations and Flame Figures: A Spectrum of Eosinophilic Dermatoses Whose Features Overlap With Wells' Syndrome. ( 25839890 )
2015
27
Comparison of two leukocytapheresis protocols in a case of idiopathic hypereosinophilic syndrome. ( 26463664 )
2015
28
Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system. ( 25843450 )
2015
29
Recurrent native and prosthetic mitral valve thrombosis in idiopathic hypereosinophilic syndrome. ( 25076546 )
2014
30
Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma. ( 25621091 )
2014
31
Idiopathic hypereosinophilic syndrome with multiple organ infarction: improvement of the skin condition masking the course of disease. ( 24667633 )
2014
32
Response to corticosteroids and cytotoxic drugs in a case of idiopathic hypereosinophilic syndrome with predominantly elevated eosinophils and multiple clinical manifestations. ( 25332568 )
2014
33
Pediatric idiopathic hypereosinophilic syndrome with Gianotti-Crosti syndrome: a novel presentation. ( 24738625 )
2014
34
Imaging diagnosis for left ventricular thrombosis in idiopathic hypereosinophilic syndrome: two case reports. ( 25275526 )
2014
35
A case of idiopathic hypereosinophilic syndrome presenting with acute respiratory distress syndrome. ( 24404401 )
2014
36
Eosinophilic cystitis and idiopathic hypereosinophilic syndrome in an eight-year-old girl. ( 25394455 )
2014
37
Catastrophic thrombosis in idiopathic hypereosinophilic syndrome. ( 24456103 )
2014
38
An unusual case of idiopathic hypereosinophilic syndrome presenting with myopericarditis and a polypoid cardiac mass. ( 24769822 )
2014
39
Two cases of acute myelitis with idiopathic hypereosinophilic syndrome. ( 24849647 )
2014
40
Pneumothorax as the initial manifestation of idiopathic hypereosinophilic syndrome. ( 25441802 )
2014
41
Idiopathic hypereosinophilic syndrome presenting as severe Loeffler's endocarditis. ( 23681213 )
2013
42
A 66-year-old man with multiple cerebral and cerebellar infarcts due to idiopathic hypereosinophilic syndrome. ( 23916764 )
2013
43
An unusual presentation of idiopathic hypereosinophilic syndrome. ( 23880718 )
2013
44
Idiopathic hypereosinophilic syndrome in children: 3 cases with review of literature. ( 22740191 )
2013
45
Can ANCA differentiate eosinophilic granulomatosis with polyangiitis (Churg-Strauss) from idiopathic hypereosinophilic syndrome? ( 24144017 )
2013
46
Chromosomal mosaicism for inversion of chromosome 3(p25, p26) in a case of idiopathic hypereosinophilic syndrome (IHES). ( 24426336 )
2013
47
Bioprosthetic valve replacement in idiopathic hypereosinophilic syndrome with mitral valve involvement. ( 24001347 )
2013
48
Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients. ( 22988896 )
2013
49
Cardiac involvement mimicking acute coronary syndrome in idiopathic hypereosinophilic syndrome. ( 24448335 )
2013
50
Ocular involvement in idiopathic hypereosinophilic syndrome: a rare finding. ( 22496024 )
2012

Variations for Hypereosinophilic Syndrome, Idiopathic

ClinVar genetic disease variations for Hypereosinophilic Syndrome, Idiopathic:

6 (show top 50) (show all 188)
# Gene Variation Type Significance SNP ID Assembly Location
1 PDGFRA NM_006206.5(PDGFRA): c.2021C> T (p.Thr674Ile) single nucleotide variant Pathogenic rs121908587 GRCh37 Chromosome 4, 55144547: 55144547
2 PDGFRA NM_006206.5(PDGFRA): c.2021C> T (p.Thr674Ile) single nucleotide variant Pathogenic rs121908587 GRCh38 Chromosome 4, 54278380: 54278380
3 PDGFRA NM_006206.5(PDGFRA): c.1019G> A (p.Arg340Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs77524207 GRCh37 Chromosome 4, 55133806: 55133806
4 PDGFRA NM_006206.5(PDGFRA): c.1019G> A (p.Arg340Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs77524207 GRCh38 Chromosome 4, 54267639: 54267639
5 PDGFRA NM_006206.5(PDGFRA): c.1285G> A (p.Gly429Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs150577828 GRCh37 Chromosome 4, 55138608: 55138608
6 PDGFRA NM_006206.5(PDGFRA): c.1285G> A (p.Gly429Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs150577828 GRCh38 Chromosome 4, 54272441: 54272441
7 PDGFRA NM_006206.5(PDGFRA): c.1432T> C (p.Ser478Pro) single nucleotide variant Benign rs35597368 GRCh37 Chromosome 4, 55139771: 55139771
8 PDGFRA NM_006206.5(PDGFRA): c.1432T> C (p.Ser478Pro) single nucleotide variant Benign rs35597368 GRCh38 Chromosome 4, 54273604: 54273604
9 PDGFRA NM_006206.5(PDGFRA): c.236G> A (p.Gly79Asp) single nucleotide variant Benign/Likely benign rs36035373 GRCh37 Chromosome 4, 55127448: 55127448
10 PDGFRA NM_006206.5(PDGFRA): c.236G> A (p.Gly79Asp) single nucleotide variant Benign/Likely benign rs36035373 GRCh38 Chromosome 4, 54261281: 54261281
11 PDGFRA NM_006206.5(PDGFRA): c.599C> G (p.Thr200Ser) single nucleotide variant Likely benign rs149951350 GRCh37 Chromosome 4, 55130065: 55130065
12 PDGFRA NM_006206.5(PDGFRA): c.599C> G (p.Thr200Ser) single nucleotide variant Likely benign rs149951350 GRCh38 Chromosome 4, 54263898: 54263898
13 PDGFRA NM_006206.5(PDGFRA): c.661C> T (p.Leu221Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs139913632 GRCh37 Chromosome 4, 55131118: 55131118
14 PDGFRA NM_006206.5(PDGFRA): c.661C> T (p.Leu221Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs139913632 GRCh38 Chromosome 4, 54264951: 54264951
15 PDGFRA NM_006206.5(PDGFRA): c.853A> G (p.Ser285Gly) single nucleotide variant Uncertain significance rs541057765 GRCh37 Chromosome 4, 55133549: 55133549
16 PDGFRA NM_006206.5(PDGFRA): c.853A> G (p.Ser285Gly) single nucleotide variant Uncertain significance rs541057765 GRCh38 Chromosome 4, 54267382: 54267382
17 PDGFRA NM_006206.5(PDGFRA): c.1122G> C (p.Arg374Ser) single nucleotide variant Benign/Likely benign rs61735622 GRCh37 Chromosome 4, 55136800: 55136800
18 PDGFRA NM_006206.5(PDGFRA): c.1122G> C (p.Arg374Ser) single nucleotide variant Benign/Likely benign rs61735622 GRCh38 Chromosome 4, 54270633: 54270633
19 PDGFRA NM_006206.5(PDGFRA): c.1135T> G (p.Leu379Val) single nucleotide variant Conflicting interpretations of pathogenicity rs199827643 GRCh38 Chromosome 4, 54270646: 54270646
20 PDGFRA NM_006206.5(PDGFRA): c.1135T> G (p.Leu379Val) single nucleotide variant Conflicting interpretations of pathogenicity rs199827643 GRCh37 Chromosome 4, 55136813: 55136813
21 PDGFRA NM_006206.5(PDGFRA): c.996C> T (p.Val332=) single nucleotide variant Benign/Likely benign rs142498442 GRCh38 Chromosome 4, 54267616: 54267616
22 PDGFRA NM_006206.5(PDGFRA): c.996C> T (p.Val332=) single nucleotide variant Benign/Likely benign rs142498442 GRCh37 Chromosome 4, 55133783: 55133783
23 PDGFRA NM_006206.5(PDGFRA): c.2778C> T (p.Tyr926=) single nucleotide variant Benign/Likely benign rs138519829 GRCh38 Chromosome 4, 54289012: 54289012
24 PDGFRA NM_006206.5(PDGFRA): c.2778C> T (p.Tyr926=) single nucleotide variant Benign/Likely benign rs138519829 GRCh37 Chromosome 4, 55155179: 55155179
25 PDGFRA NM_006206.5(PDGFRA): c.201C> T (p.Ser67=) single nucleotide variant Benign/Likely benign rs35805947 GRCh37 Chromosome 4, 55127413: 55127413
26 PDGFRA NM_006206.5(PDGFRA): c.201C> T (p.Ser67=) single nucleotide variant Benign/Likely benign rs35805947 GRCh38 Chromosome 4, 54261246: 54261246
27 PDGFRA NM_006206.5(PDGFRA): c.276G> A (p.Ala92=) single nucleotide variant Likely benign rs140725151 GRCh38 Chromosome 4, 54261321: 54261321
28 PDGFRA NM_006206.5(PDGFRA): c.276G> A (p.Ala92=) single nucleotide variant Likely benign rs140725151 GRCh37 Chromosome 4, 55127488: 55127488
29 PDGFRA NM_006206.5(PDGFRA): c.801A> G (p.Pro267=) single nucleotide variant Conflicting interpretations of pathogenicity rs55966236 GRCh38 Chromosome 4, 54267330: 54267330
30 PDGFRA NM_006206.5(PDGFRA): c.801A> G (p.Pro267=) single nucleotide variant Conflicting interpretations of pathogenicity rs55966236 GRCh37 Chromosome 4, 55133497: 55133497
31 PDGFRA NM_006206.5(PDGFRA): c.1320G> A (p.Thr440=) single nucleotide variant Benign/Likely benign rs56026726 GRCh37 Chromosome 4, 55138643: 55138643
32 PDGFRA NM_006206.5(PDGFRA): c.1320G> A (p.Thr440=) single nucleotide variant Benign/Likely benign rs56026726 GRCh38 Chromosome 4, 54272476: 54272476
33 PDGFRA NM_006206.5(PDGFRA): c.1731G> A (p.Pro577=) single nucleotide variant Benign/Likely benign rs55830582 GRCh37 Chromosome 4, 55141085: 55141085
34 PDGFRA NM_006206.5(PDGFRA): c.1731G> A (p.Pro577=) single nucleotide variant Benign/Likely benign rs55830582 GRCh38 Chromosome 4, 54274918: 54274918
35 PDGFRA NM_006206.5(PDGFRA): c.1891C> T (p.Pro631Ser) single nucleotide variant Likely benign rs199902153 GRCh38 Chromosome 4, 54277492: 54277492
36 PDGFRA NM_006206.5(PDGFRA): c.1891C> T (p.Pro631Ser) single nucleotide variant Likely benign rs199902153 GRCh37 Chromosome 4, 55143659: 55143659
37 PDGFRA NM_006206.5(PDGFRA): c.2742G> C (p.Arg914=) single nucleotide variant Conflicting interpretations of pathogenicity rs56384252 GRCh37 Chromosome 4, 55155033: 55155033
38 PDGFRA NM_006206.5(PDGFRA): c.2742G> C (p.Arg914=) single nucleotide variant Conflicting interpretations of pathogenicity rs56384252 GRCh38 Chromosome 4, 54288866: 54288866
39 PDGFRA NM_006206.5(PDGFRA): c.3156G> A (p.Thr1052=) single nucleotide variant Benign/Likely benign rs55996208 GRCh37 Chromosome 4, 55161325: 55161325
40 PDGFRA NM_006206.5(PDGFRA): c.3156G> A (p.Thr1052=) single nucleotide variant Benign/Likely benign rs55996208 GRCh38 Chromosome 4, 54295158: 54295158
41 PDGFRA NM_006206.5(PDGFRA): c.3228C> T (p.Ile1076=) single nucleotide variant Benign/Likely benign rs148629782 GRCh37 Chromosome 4, 55161397: 55161397
42 PDGFRA NM_006206.5(PDGFRA): c.3228C> T (p.Ile1076=) single nucleotide variant Benign/Likely benign rs148629782 GRCh38 Chromosome 4, 54295230: 54295230
43 PDGFRA NM_006206.5(PDGFRA): c.368-3C> T single nucleotide variant Benign/Likely benign rs55947416 GRCh38 Chromosome 4, 54263664: 54263664
44 PDGFRA NM_006206.5(PDGFRA): c.368-3C> T single nucleotide variant Benign/Likely benign rs55947416 GRCh37 Chromosome 4, 55129831: 55129831
45 PDGFRA NM_006206.5(PDGFRA): c.612T> C (p.Asn204=) single nucleotide variant Benign rs2229307 GRCh38 Chromosome 4, 54263911: 54263911
46 PDGFRA NM_006206.5(PDGFRA): c.612T> C (p.Asn204=) single nucleotide variant Benign rs2229307 GRCh37 Chromosome 4, 55130078: 55130078
47 PDGFRA NM_006206.5(PDGFRA): c.939T> G (p.Gly313=) single nucleotide variant Benign rs4358459 GRCh37 Chromosome 4, 55133726: 55133726
48 PDGFRA NM_006206.5(PDGFRA): c.939T> G (p.Gly313=) single nucleotide variant Benign rs4358459 GRCh38 Chromosome 4, 54267559: 54267559
49 PDGFRA NM_006206.5(PDGFRA): c.1701A> G (p.Pro567=) single nucleotide variant Benign rs1873778 GRCh37 Chromosome 4, 55141055: 55141055
50 PDGFRA NM_006206.5(PDGFRA): c.1701A> G (p.Pro567=) single nucleotide variant Benign rs1873778 GRCh38 Chromosome 4, 54274888: 54274888

Copy number variations for Hypereosinophilic Syndrome, Idiopathic from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 120036 18 19523559 19789027 Insertion LAMA3 Idiopathic hypereosinophilic syndrome
2 187722 4 53938619 54020599 Translate FIP1L1 Idiopathic hypereosinophilic syndrome

Expression for Hypereosinophilic Syndrome, Idiopathic

Search GEO for disease gene expression data for Hypereosinophilic Syndrome, Idiopathic.

Pathways for Hypereosinophilic Syndrome, Idiopathic

Pathways related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 IL3 IL5 KIT PDGFRA PDGFRB TGFA
2
Show member pathways
13.31 IL3 KIT PDGFRA PDGFRB TGFA
3
Show member pathways
13.28 IL3 IL5 KIT PDGFRA PDGFRB TGFA
4
Show member pathways
13.26 IL3 IL5 KIT PDGFRA PDGFRB
5
Show member pathways
13.14 IL3 IL5 KIT PDGFRA PDGFRB
6
Show member pathways
13.1 IL3 KIT PDGFRA PDGFRB TGFA
7
Show member pathways
13.06 IL3 KIT PDGFRA PDGFRB TGFA
8
Show member pathways
13.06 IL3 IL5 KIT PDGFRA PDGFRB TGFA
9
Show member pathways
12.91 IL3 IL5 KIT PDGFRA PDGFRB TGFA
10
Show member pathways
12.81 IL3 KIT PDGFRA PDGFRB TGFA
11
Show member pathways
12.78 IL3 KIT PDGFRA PDGFRB TGFA
12
Show member pathways
12.7 IL3 KIT PDGFRA PDGFRB TGFA
13 12.57 KIT PDGFRA PDGFRB TGFA
14
Show member pathways
12.55 IL3 KIT PDGFRA PDGFRB TGFA
15
Show member pathways
12.53 KIT PDGFRA PDGFRB TGFA
16
Show member pathways
12.25 IL5 PDGFRA PDGFRB
17
Show member pathways
12.21 KIT PDGFRA PDGFRB
18
Show member pathways
12.18 IL3 IL5 PDGFRA PDGFRB
19 12.15 IL3 IL5 KIT PDGFRA PDGFRB TGFA
20
Show member pathways
12.02 IL3 KIT PDGFRA PDGFRB TGFA
21 11.9 IL3 PDGFRB WT1
22
Show member pathways
11.87 IL3 IL5 TGFA
23 11.82 IL3 IL5 KIT
24 11.74 IL3 IL5 KIT
25 11.73 KIT PDGFRA PDGFRB TGFA
26 11.68 PDGFRA PDGFRB TGFA
27
Show member pathways
11.61 KIT PDGFRA PDGFRB
28 11.53 IL3 PDGFRA PDGFRB TGFA
29 11.47 KIT PDGFRA PDGFRB
30 11.4 KIT PDGFRA
31 11.35 IL3 KIT
32 11.35 IL3 IL5
33 11.32 PDGFRA PDGFRB
34
Show member pathways
11.31 IL3 IL5 KIT PDGFRA PDGFRB TGFA
35 11.28 PDGFRA PDGFRB
36 11.1 IL3 IL5
37 10.99 PDGFRA PDGFRB
38 10.76 PDGFRA PDGFRB
39 10.54 IL3 IL5 KIT PDGFRA PDGFRB TGFA

GO Terms for Hypereosinophilic Syndrome, Idiopathic

Cellular components related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intrinsic component of plasma membrane GO:0031226 9.16 PDGFRA PDGFRB
2 receptor complex GO:0043235 9.13 KIT PDGFRA PDGFRB
3 cell surface GO:0009986 8.92 KIT PDGFRA PDGFRB TGFA

Biological processes related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.83 IL3 IL5 KIT
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 KIT PDGFRA PDGFRB
3 positive regulation of cell migration GO:0030335 9.82 KIT PDGFRA PDGFRB
4 protein autophosphorylation GO:0046777 9.8 KIT PDGFRA PDGFRB
5 positive regulation of protein kinase B signaling GO:0051897 9.79 KIT PDGFRA PDGFRB
6 positive regulation of MAPK cascade GO:0043410 9.77 KIT PDGFRA PDGFRB
7 negative regulation of apoptotic process GO:0043066 9.77 KIT PDGFRA PDGFRB TGFA WT1
8 negative regulation of signal transduction GO:0009968 9.76 KIT PDGFRA PDGFRB
9 phosphatidylinositol phosphorylation GO:0046854 9.75 KIT PDGFRA PDGFRB
10 male gonad development GO:0008584 9.74 KIT PDGFRB WT1
11 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.73 KIT PDGFRA PDGFRB
12 wound healing GO:0042060 9.72 PDGFRA PDGFRB TGFA
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 IL3 IL5 TGFA
14 cell chemotaxis GO:0060326 9.67 KIT PDGFRA PDGFRB
15 positive regulation of fibroblast proliferation GO:0048146 9.66 PDGFRA PDGFRB
16 phosphatidylinositol-mediated signaling GO:0048015 9.66 PDGFRA PDGFRB
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 KIT PDGFRA PDGFRB
18 platelet-derived growth factor receptor signaling pathway GO:0048008 9.64 PDGFRA PDGFRB
19 positive regulation of mitotic nuclear division GO:0045840 9.64 PDGFRB TGFA
20 positive regulation of JAK-STAT cascade GO:0046427 9.63 IL5 KIT
21 adrenal gland development GO:0030325 9.63 PDGFRA WT1
22 cardiac myofibril assembly GO:0055003 9.61 PDGFRA PDGFRB
23 male genitalia development GO:0030539 9.61 PDGFRA WT1
24 embryonic hemopoiesis GO:0035162 9.6 IL3 KIT
25 MAPK cascade GO:0000165 9.55 IL3 IL5 KIT PDGFRA PDGFRB
26 metanephric mesenchyme development GO:0072075 9.54 PDGFRB WT1
27 retina vasculature development in camera-type eye GO:0061298 9.52 PDGFRA PDGFRB
28 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.5 KIT PDGFRA PDGFRB
29 metanephric S-shaped body morphogenesis GO:0072284 9.46 PDGFRB WT1
30 metanephric glomerular capillary formation GO:0072277 9.43 PDGFRA PDGFRB
31 positive regulation of phospholipase C activity GO:0010863 9.43 KIT PDGFRA PDGFRB
32 positive regulation of cell proliferation GO:0008284 9.43 IL3 IL5 KIT PDGFRA PDGFRB TGFA
33 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.4 PDGFRA PDGFRB
34 peptidyl-tyrosine phosphorylation GO:0018108 9.02 IL3 IL5 KIT PDGFRA PDGFRB

Molecular functions related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.63 KIT PDGFRA PDGFRB
2 growth factor activity GO:0008083 9.61 IL3 IL5 TGFA
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 KIT PDGFRA PDGFRB
4 platelet-derived growth factor receptor binding GO:0005161 9.4 PDGFRA PDGFRB
5 platelet-derived growth factor binding GO:0048407 9.37 PDGFRA PDGFRB
6 protein tyrosine kinase activity GO:0004713 9.35 IL3 IL5 KIT PDGFRA PDGFRB
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 KIT PDGFRA PDGFRB
8 vascular endothelial growth factor binding GO:0038085 9.32 PDGFRA PDGFRB
9 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.02 IL3 IL5 KIT PDGFRA PDGFRB

Sources for Hypereosinophilic Syndrome, Idiopathic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....